We quantified ATM protein expression in four of the families and found variable ATM protein expression (0-6.4%), further evidence for mutant ATM protein expression in both classic and variant A-T patients. We conclude that FCCM offers a robust ATM mutation detection method and can be used to screen for ATM mutations in cancer-prone populations.
Introduction
Ataxia telangiectasia (A-T) is an autosomal recessive disease affecting 1/40 000 to 1/300 000 individuals worldwide. 1, 2 This complex disorder is characterised by progressive cerebellar degeneration, oculocutaneous telangiectasia, oculomotor apraxia, immunodeficiency, raised serum α-fetoprotein (AFP), chromosomal instability, radiosensitivity, and a 100-fold increase in cancer susceptibility, with lymphoreticular malignancies predominating. 3 Epidemiological studies have reported increased cancer susceptibility in A-T heterozygotes, particularly to breast cancer in women, 4 but debate continues over the role of A-T carrier status in breast cancer predisposition. 5 The A-T gene, Ataxia Telangiectasia Mutated (ATM), was mapped to chromosome 11q22-23 in 1988, 6 and was isolated by positional cloning in 1995. 7 ATM is a large, complex gene, with 66 exons, spanning over 150 kb, with the start codon in exon 4. 8, 9 This generates a 13 kb transcript, with an open reading frame of 9168 bp, predicting a protein of 3056 amino acids. 10 The ATM protein (about 350 kDa) is located primarily in the nucleus of normal cells 11 and has homology at its carboxy terminus to phosphatidylinositol (PI) 3-kinase. Related proteins that share PI 3-kinase domain homology are found in yeast (TEL1, MEC1, Rad3, TOR1, and TOR2), Drosophila (Mei-41) and mammals (DNA-PK), (Savitsky et al 10 for a review). PI 3-kinase family members are involved in a wide variety of regulatory events, including processing DNA damage, maintenance of genome stability and control of cell cycle progression. 10 Over 250 ATM mutations have been reported to date, spanning the entire coding region. 12 No mutational hotspots have been found, although some founder mutations have been identified. 13, 14 Most groups have developed scanning methods using cDNA to identify ATM mutations. Techniques include PTT, 15 SSCP, 16 RNAse cleavage, 17 and REF. 18 Others have used direct sequencing of cDNA. 19 The overall mutation detection rate has been high (about 70%), with base substitutions, small deletions and insertions predominating, resulting in truncation of the ATM protein. 12 An increasing number of in-frame deletions and missense mutations have recently been described. 13 We chose solid-phase fluorescent chemical cleavage of mismatch (FCCM) to screen the entire ATM transcript, because it offers efficient and sensitive mutation detection, without bias towards any particular mutation type. Solid-phase FCCM has been used to detect mutations in other large, complex genes, eg Factor IX 20 and BRCA1, 21 with almost 100% accuracy, 20 locating any sequence change in long DNA segments (up to 1.8 kb). We describe its adaptation to detect ATM mutations using cDNA, with the aim of characterising mutations in A-T families for development of mutation-based prenatal diagnosis. This method is being extended to screen breast cancer patients for germline ATM mutations. In this study, we describe the identification of seven ATM mutations in five A-T families screened using FCCM, (four of which have not been previously identified), and examine expression of the mutant ATM protein.
Materials and Methods

Patients
Five non-consanguineous A-T families gave informed consent for this study. Their clinical features are listed in Table 1 . Family 347 had two affected daughters; all other families had one affected child. The affected individuals, A-T 347, A-T 352, A-T 451, and A-T 537 have a classic A-T phenotype, whilst A-T 350 exhibits a variant A-T phenotype. 22 
Controls
DNA was isolated from 50 Caucasian males without a family history of A-T or cancer. BD2685 is a lymphoblastoid cell line (LCL) established from a breast cancer patient, negative for ATM mutations screened by FCCM. Molt 4 is a T cell LCL.
Molecular Methods
DNA and RNA were isolated from peripheral blood samples by standard methods. 23, 24 Reverse transcription was performed on 0.5-1 µg of total RNA with 0.5 µg random hexamers primer. 25 The ATM coding sequence was amplified from patientderived cDNAs by nested PCR, in eight first round reactions, serving as templates for nine overlapping second round reactions, 0.9 to 1.7 kb in size ( Figure 1 ).
Careful primer design allowed all primary and nested RT-PCR reactions to be amplified using one of two sets of conditions (primer details, Table 2 ). The PCR reaction mixture contained 200 µM dNTPs, 500 nM of each primer set (Table 2 ), 1.5 mM MgCl 2 Taq buffer (Promega, Southampton, (Figure 1) . PCR conditions for first round PCR for all fragments, except 1AF/2BR (Figure 1 ), comprised 30 cycles of 94°C, 30 s, 55°C, 30 s, and 72°C, 2 min, followed by a 10 min extension at 72°C. Touchdown PCR 26 was used to amplify second round PCR reactions, fragment 1AF/2BR (Figure 1) , the promoter fragment, and all probes. Conditions used were as follows: 30 cycles of 94°C, 30 s, 64°C, 30 s (for 5 cycles, then 60°C for 25 cycles), and 68°C, 90 s, and final extension at 68°C for 5 min. The promoter region was amplified from 100 ng of genomic DNA. Probe DNA was amplified using a modified second round primer set, (each primer biotinylated at the 5' end), internally labelled with [F]dUTPs, and gel-purified. cDNA clones (FB2-f, FB-2 and 7-9) 10 and a partial subclone of En-a (extending from -30 to 2028; Nucleotide numbering according to Savitsky et al 10 ), 48 served as probe templates (Figure 1 ), except for fragment III, where a PCR product of known sequence was used.
Mutation Detection
Solid-phase fluorescent chemical cleavage of mismatch (FCCM) was used to identify ATM mutations 20 with modifications detailed below.
Three separate, non-overlapping multiplexes were formed by labelling nested PCR fragments as described (see legend, Figure 1 ). 1 µl of each biotinylated internally labelled probe, was combined with 4 µl internally labelled target per multiplex, favouring maximum heteroduplex formation between probe and patient DNA. Heteroduplex formation and chemical mismatch were as described, 20 using hydroxylamine and osmium tetroxide modification sequentially.
2 µl of supernatant was loaded on a 6% polyacrylamide/ urea gel (34 lane, 12 cm well-to-read plates) on the ABI 377 DNA sequencer and separated by electrophoresis at 50 W for 10 b nucleotide numbers refer to the genomic sequence with the first nucleotide designated +1, GDB: 47 U82828 Platzer et al; 9 c the overlap, in base pairs, corresponds to the overlap between that fragment and the 5' neighbouring fragment.
Rapid and efficient ATM mutation detection L Izatt et al t 5-7 h using GS12A-2400. Data was collected and analysed using Genescan 2.02 software (ABI Prism, Warrington, U.K.).
DNA Sequencing and Restriction Assays
RT-PCR was repeated without labelling, and products sequenced in both directions. 27 Sequence variants were confirmed by PCR and sequencing genomic DNA, using primers listed (Table 2) .
For the L1465P mutation, a naturally occurring restriction site was created in exon 31 by the base substitution, allowing XhoI digestion in mutant alleles.
Cell Lines/Western Blotting
Control BD2685, and four A-T patient LCLs were cultured in RPMI 1640 (Gibco BRL, Paisley, U.K.) with 10% foetal calf serum. Total cellular lysate preparation was as described. 14 50 µg protein was loaded per lane, separated electrophoretically through 7.5% SDS-Polyacrylamide gels, and blotted on to nitrocellulose membranes (ImmobilonP-Millipore, Bedford, MA, USA) by semi-dry transfer. ATM protein was detected with a polyclonal antiserum (CN-12) raised against a recombinant polypeptide corresponding to 992-1144 of ATM protein. A -tubulin monoclonal antibody (Amersham, Little Chalfont, Bucks, U.K.) was used to quantitate protein loading. Western blotting was as described 28 and blots were developed by enhanced chemiluminescence (Amersham). Protein levels were measured using the BioImage Whole Band Analyser system (Millipore), normalised against -tubulin readings, using BD2685 as a standard.
Results
FCCM on Patient Samples
The optimised multiplexed FCCM technique was used to screen A-T patient samples, allowing analysis of the entire ATM coding region of up to ten patients per gel. Cleavage bands detected by Genescan analysis were used to predict the mismatched base site within the fragment (Figures 2A and 2B ). Accurate sizing of the two separate cleavage products on the electropherogram enables location of the mismatched base to within 10-15 bp of one of two sites in the fragment screened ( Figures 2C and 2D) . Seven different ATM mutations were detected in five A-T families analysed ( Table 3) . Four of these, 480del5, 1158delG, IVS22-1G→A, and 4394T→C, are novel.
Frameshift Mutations
The 480del5 mutation in ATM exon 7 detected in A-T 347 was seen in both affected siblings in this family and f =137bp of intron 40 aberrantly spliced into the A-T transcript between exon 40 and 41; mutations were confirmed by amplification and sequence analysis of genomic PCR products using primers listed in Table 2 .
Rapid and efficient ATM mutation detection L Izatt et al t their father (results not shown) ( Table 3) . Sequencing of the RT-PCR product in A-T 347 showed bi-allelic expression (results not shown). This 5 bp deletion (underlined) is associated with a direct repeat (italicised) in the DNA sequence TATCTCAGCAACA. The 1158delG mutation in ATM exon 11 was detected in A-T 537 and his mother (results not shown) ( Table 3 ; Figure 3A ). This deletion (underlined) occurs in a run of homonucleotides (italicised) CAAAAGGAAGA. These two deletions may occur as a result of DNA slippage during replication. The 1355delC in ATM exon 12, found in A-T 451, (Table 3) was described previously. 13 
Splicing Mutations
Two close mismatch bands were detected in fragment IV from A-T 537 ( Figures 2B and 2D ). Sequencing cDNA across this region identified exon 23 skipping in A-T 537 ( Figure 3B ), deleting 76 bp, resulting in a frameshift in exon 24 (Table 3 ). Sequence analysis of genomic DNA from A-T 537 revealed IVS22-1G→A at the intron 22-exon 23 splicing junction ( Figure 3C ; Table 3 ). This mutation alters the invariant splicing acceptor site from AG to AA, explaining the observed exon 23 skipping ( Figure 3B ). This splicing variant is unlikely to occur in the absence of the splice site mutation, because it was not observed in FCCM analysis of 250 chromosomes from A-T and breast cancer families, but was found in the father of A-T 537 (results not shown). IVS40-1050A→G, found in A-T 350, was described previously, 29 (Table 3) .
Nonsense/Missense Mutations
The 4394T→C base substitution found in ATM exon 31 in A-T 451 results in a leucine-to-proline amino acid substitution at codon 1465 (Table 3 ). This base change creates an XhoI cutting site in the exon 31 PCR product of 294 bp. Upon digestion, the mutant allele gives rise to two fragments of 206 bp and 88 bp, while the normal allele is resistant to XhoI digestion, giving an undigested fragment of 294 bp (Figure 4 ). 4394T→C, is unlikely to be a polymorphism, since this base change was not detected after PCR and XhoI digestion of 100 control chromosomes (results not shown), and because leucine is conserved at this position in mouse Atm.
30
The 9139C→T single base substitution in ATM exon 65 found in A-T 350 creates a stop codon at 3047, with loss of ten amino acids from the C-terminus of the protein. This mutation has been described previously. 29 Two other coding sequence variations were detected in A-T 537 and A-T 451, both patients being heterozygous for polymorphism 5557G/A (exon 39). No sequence variations were detected in A-T 352.
Western Blotting
ATM protein expression was investigated in four of the A-T families where LCLs were available, to examine the consequences of different ATM mutations on protein expression and clinical phenotype ( Figure 5 ). The highest amount of full-length ATM protein observed (6.4%) was in A-T 350 ( Figure 5 ). The presence of full-length ATM protein occurs as a result of some normal splicing at IVS40-1050A→G, 29 and expression of some stable minimally truncated ATM protein from 9139C→T. 31 This patient exhibits a variant phenotype (Table 1) . A-T 451 and A-T 347 have classic phenotypes (Table 1 ) and significantly reduced fulllength ATM expression ( Figure 5 ). Each has one truncated A-T allele upstream of the antibody-binding site ( Table 3 ), so that any ATM protein detected must arise from the second allele. In A-T 451, the low level of ATM expression shown (1%) ( Figure 5 ) indicates that the L1465P missense mutation (Table 3) 
Mutant Allele Origins
Three of the five families studied were native to the British Isles. Family 537, and the father of A-T 347 were of Celtic/Irish origin, whilst the mother of A-T 347 was of Greek-Cypriot origin (Table 3) . Only one mutation, IVS40-1050A→G, has previously been shown to be a founder mutation in the British Isles. 29 Although 9139C→T has been described in an Italian, 31 Japanese, 17 and UK families, no common haplotype was reported. 13 We identified all three alleles of Celtic/Irish origin, each mutation being novel to this study (Table 3) .
Discussion
We have shown that FCCM is an effective mutation detection method in scanning the entire ATM coding region for mutations. Our study identified seven out of a possible ten ATM mutations in five A-T families, giving a sensitivity of 70%, comparable with other ATM mutation detection methods used, eg PTT 15 and REF. Rapid and efficient ATM mutation detection L Izatt et al t changes is seen, increasing sensitivity and detection. 20 If differential mRNA expression of each mutant allele occurs, the sensitivity of FCCM may enable detection of as little as 10% of the mutant transcript. 32 Finally, because analysis of FCCM gels is automated, comparisons between samples are easier.
The seven ATM mutations detected in this study reflect the spectrum of ATM mutations already characterised worldwide, with small deletions and exonskipping mutations predominating. Although ATM mutations are found to span the entire open reading frame, our small study showed three deletions occurring in exons 7-12. Exon-skipping mutations have been reported to involve at least 34 of the 66 exons in ATM, but only in about 20% of instances has the underlying genomic mutation been reported. 33 We found exon 23 skipping in A-T 537, as a consequence of IVS22-IG→A. Exon skipping is the commonest outcome following a mutation in the acceptor splice site; however, cryptic splice site activation, intron retention, and new splice site creation can occur. 34 There has been one previous description of exon 23 skipping, in tandem with exon 24, but the underlying genomic mutation was not reported. 16 We detected one new missense mutation (L1465P) in ATM, adding to the 24 already reported in A-T patients. 33 This mutation leads to a proline substitution in the middle of a predicted α-helix from amino acids 1460 to 1476 (consensus predictions generated by Jpred, 35 a protein prediction algorithm service). This is predicted to change the secondary structure of the protein, destabilising the protein. 36 Examples of leucine-to-proline substitutions resulting in protein instability are reasonably common, eg L12P in λ repressor. 37 We observed reduced ATM protein expression from this allele in A-T 451, in keeping with this prediction.
By demonstrating reduced or absent ATM protein expression in four cases, we were able to confirm the diagnosis of A-T. Residual ATM protein expression is often associated with alleles harbouring 'leaky' splicing mutations, 31 as seen in A-T 350, or in-frame deletions, or missense mutations, as seen in A-T 451. Correlation of expressed ATM protein levels with clinical and cellular phenotypic features is difficult, because 'variant' A-T patients have been shown to express 1-100% of the normal level of ATM protein, 13, 31 and this overlaps with the protein levels seen in classic A-T patients. 13 Several founder mutations have been described in ATM, including eleven recurrent ATM mutations in the British Isles. 13 Two of these, 2639del200nt (codon 880), and 7639del9nt (codon 2546-2548), were found in families of Irish/Celtic descent. 38 Three of our A-T alleles were of Celtic/Irish origin, but did not share these founder mutations.
Three ATM alleles were not detected in this study, despite analysing the ATM/E14 bi-directional promoter region for mutations. ATM promoter mutations have not been found in A-T patients, 39 but bi-allelic deletion of 5' exons of ATM, has been observed in T-prolymphocytic leukaemia tumour DNA. 40 Possible explanations for non-detection of these three mutations include technical difficulties in FCCM, absent mRNA expression and other types of mutations, not detectable by RT-PCR analysis, eg gross deletions/insertions of the gene, RNA editing, position effect variegation, 41 or gene modifiers altering expression or function of ATM. 42 The sensitivity of FCCM had previously been tested against a panel of eight known and seven 'blind' ATM mutations and all were detected (details not shown), making technical limitation of FCCM unlikely. Evidence for both mutant mRNA alleles being expressed was seen in all patients, except A-T 352, where no coding sequence variations were found. ATM has a relative paucity of coding sequence variants (5557G/A found in 0.82/0.18, 43 is the most common), and therefore verifying that both mRNA alleles are expressed at adequate levels may prove impossible. One of the undetected ATM mutations in A-T 352 may be a regulatory mutation in remote promoter elements, as reported for other genes, eg BRCA1, 27 or may destabilise the mRNA so that only a single copy of the transcript is amplified. 44 In summary, we have shown FCCM to be a fast, accurate and sensitive method for detecting mutations in ATM and have examined the resultant protein expression patterns in four A-T families. Three of the four novel mutations described are from Celtic/Irish families, which extends the known mutation repertoire in this population. The detection of both ATM mutations in three families, allows us to offer direct mutation-based prenatal tests for A-T in future pregnancies, which is preferable to and more accurate than the radiosensitive chromosomal breakage assay or linkage analysis. Finally, having confirmed the efficacy of FCCM, we can now use FCCM in further studies, testing the hypothesis that A-T heterozygotes may have increased susceptibility to breast cancer.
